|Articles|May 5, 2003
Santen submits NDA for levofloxacin 1.5%
Santen Pharmaceuticals Co. filed a New Drug Application with the FDAon Monday for levofloxacin 1.5%, the company's new ocular anti-infectivedrug.The larger concentration of Levofloxacin is a potent, broad-spectrumantibiotic. The company reports that Levofloxacin's higher solubility, atneutral pH, allows the drug to be formulated at a higher concentration thanother fluoroquinolones on the market.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Ocular Therapeutix reaches target enrollment of 555 patients in SOL-R trial
2
4DMT and Otsuka Pharmaceutical partner on 4D-150 in the greater Asia-Pacific region
3
AAVantgarde Bio closes $141 million Series B financing round
4














































.png)


